Phase 2/3 clinical trial data readouts for lead programs (etrumadenant combinations in colorectal cancer, non-small cell lung cancer, renal cell carcinoma)
FDA regulatory milestone achievements including IND clearances, breakthrough therapy designations, and NDA/BLA submission timelines
Partnership expansion announcements or amendments with Gilead, Taiho, or new strategic collaborators including upfront/milestone payment disclosures
Competitive landscape developments in adenosine pathway and HIF-2α inhibitor space (Merck's MK-1308, Bristol Myers Squibb's BMS-986179, Corvus' ciforadenant)
low - Clinical-stage biotechnology operates largely independent of GDP fluctuations as revenue derives from partnership agreements rather than consumer or industrial demand. R&D spending follows scientific timelines rather than economic cycles. However, severe recessions can impact: (1) equity financing availability for cash runway extension, (2) pharmaceutical partner willingness to fund early-stage collaborations, and (3) hospital/clinical site capacity for trial enrollment during healthcare system stress.
Rising interest rates create moderate negative pressure through two mechanisms: (1) Valuation compression as discount rates increase for long-duration cash flows (clinical-stage assets have 5-10 year commercialization timelines, making NPV highly rate-sensitive), and (2) Opportunity cost dynamics where risk-free rates above 4-5% reduce investor appetite for speculative biotech equity versus fixed income alternatives. However, the $400M+ cash position generates offsetting interest income (estimated $15-20M annually at 4-5% rates). Financing costs remain minimal given low debt/equity ratio of 0.25.
Clinical trial failure risk inherent to oncology drug development (historical Phase 3 success rates approximately 30-40% in immuno-oncology, with binary stock impact of 40-60% on pivotal readouts)
Regulatory pathway uncertainty as FDA standards for combination immunotherapy approvals evolve, particularly for novel mechanism agents requiring differentiated efficacy versus established checkpoint inhibitors
Reimbursement pressure as payers scrutinize high-cost oncology therapies (typical immuno-oncology drugs priced $150-200K annually), requiring strong overall survival or quality-of-life benefits for favorable coverage
growth - Arcus attracts speculative growth investors and biotech-specialized funds seeking asymmetric risk/reward profiles tied to binary clinical catalysts. The 78% one-year return and 87% six-month return reflect momentum-driven trading around positive clinical data and partnership news. Institutional ownership skews toward healthcare-focused hedge funds and venture capital crossover investors comfortable with clinical-stage risk. Not suitable for income investors (no dividend) or value investors (negative earnings, high price/sales multiple of 8.2x). The stock appeals to catalyst-driven traders positioning ahead of data readouts and regulatory milestones.
Trend
+14.0% vs SMA 50 · +38.7% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $246.5M $238.8M–$262.0M | — | -$3.55 | — | ±9% | High8 |
FY2026(current) | $91.2M $53.5M–$237.2M | ▼ -63.0% | -$3.83 | — | ±40% | High9 |
FY2027 | $109.5M $23.1M–$208.2M | ▲ +20.1% | -$3.33 | — | ±34% | High9 |
New York, New York--(Newsfile Corp. - May 2, 2026) - WHY: Rosen Law Firm, a global investor rights l…
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
RCUS◀ | $25.68 | +0.71% | $2.6B | — | -426.4% | -14291.5% | 1500 |
| $68.56 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $513.72 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $87.60 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $183.72 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $206.53 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $74.81 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.48% | — | 40.5 | +341847.8% | -5467.5% | 1500 |